SRRK Insider Trading
Scholar Rock Holding Corp | Biological Products, (No Diagnostic Substances)
Comprehensive Trading Performance Summary
The investment history of corporate insiders at Scholar Rock Holding Corp provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Biological Products, (No Diagnostic Substances) sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2026-02-26 01:55 | 2026-02-23 | Qatanani Mo | Officer - CHIEF SCIENTIFIC OFFICER | SELL | $47.07 | 8,484 | $399,350 | 98,445 | -7.9% |
| 2026-02-20 00:30 | 2026-02-17 | Qatanani Mo | Officer - CHIEF SCIENTIFIC OFFICER | SELL | $46.53 | 7,989 | $371,714 | 106,929 | -7.0% |
| 2026-02-20 00:30 | 2026-02-17 | Parlavecchio Caryn | Officer - CHRO | SELL | $46.53 | 9,035 | $420,382 | 169,087 | -5.1% |
| 2026-02-20 00:30 | 2026-02-17 | Ho Junlin | Officer - GENERAL COUNSEL | SELL | $46.53 | 9,580 | $445,740 | 241,545 | -3.8% |
| 2026-02-20 00:30 | 2026-02-17 | Marantz Jing L. | Officer - CHIEF MEDICAL OFFICER | SELL | $46.53 | 4,157 | $193,418 | 126,012 | -3.2% |
| 2026-01-24 00:30 | 2026-01-22 | Qatanani Mo | Officer - CHIEF SCIENTIFIC OFFICER | SELL | $46.71 | 14,898 | $695,938 | 85,660 | -14.8% |
| 2026-01-22 03:52 | 2026-01-16 | Qatanani Mo | Officer - CHIEF SCIENTIFIC OFFICER | SELL | $44.48 | 8,406 | $373,880 | 100,558 | -7.7% |
| 2026-01-22 03:51 | 2026-01-16 | Parlavecchio Caryn | Officer - CHRO | SELL | $44.48 | 6,600 | $293,553 | 148,864 | -4.2% |
| 2026-01-22 03:50 | 2026-01-16 | Ho Junlin | Officer - GENERAL COUNSEL | SELL | $44.48 | 8,016 | $356,533 | 214,553 | -3.6% |
| 2026-01-22 03:50 | 2026-01-16 | Marantz Jing L. | Officer - CHIEF MEDICAL OFFICER | SELL | $44.48 | 5,798 | $257,882 | 95,687 | -5.7% |
| 2026-01-17 02:37 | 2026-01-14 | Qatanani Mo | Officer - CHIEF SCIENTIFIC OFFICER | OPT+S | $45.20 | 13,112 | $592,611 | 108,964 | 0.0% |
| 2026-01-16 03:57 | 2026-01-13 | Woods Keith | Officer - Chief Operating Officer | SELL | $42.70 | 16,746 | $715,054 | 583,254 | -2.8% |
| 2026-01-16 03:56 | 2026-01-13 | Vaishnaw Akshay | Director, Officer - President of R&D | SELL | $42.70 | 20,438 | $872,703 | 595,767 | -3.3% |
| 2026-01-16 03:54 | 2026-01-13 | Hallal David | Director, Officer - Chief Executive Officer | SELL | $42.70 | 57,450 | $2,453,115 | 1,541,645 | -3.6% |
| 2026-01-16 03:58 | 2026-01-13 | Sinha Vikas | Officer - Chief Financial Officer | SELL | $42.70 | 16,755 | $715,439 | 583,245 | -2.8% |
| 2025-12-19 00:30 | 2025-12-16 | Peng Katie | Director | SELL | $44.09 | 1,006 | $44,352 | 32,908 | -3.0% |
| 2025-12-17 05:07 | 2025-10-07 | AKKARAJU SRINIVAS | Director | BUY | $39.92 | 29,599 | $1,181,634 | 530,038 | +5.9% |
| 2025-12-06 00:53 | 2025-12-04 | Qatanani Mo | Officer - CHIEF SCIENTIFIC OFFICER | OPT+S | $45.21 | 136,462 | $6,169,788 | 108,964 | 0.0% |
| 2025-10-08 03:59 | 2025-10-03 | AKKARAJU SRINIVAS | Director | BUY | $37.58 | 500,439 | $18,807,348 | 500,439 | +100.0% |
| 2025-09-24 23:30 | 2025-09-22 | Qatanani Mo | Officer - CHIEF SCIENTIFIC OFFICER | SELL | $30.67 | 3,353 | $102,846 | 108,964 | -3.0% |
| 2025-09-17 23:30 | 2025-09-16 | Peng Katie | Director | SELL | $32.53 | 1,006 | $32,726 | 33,914 | -2.9% |
| 2025-09-17 23:30 | 2025-09-16 | Qatanani Mo | Officer - CHIEF SCIENTIFIC OFFICER | SELL | $33.52 | 3,178 | $106,527 | 112,317 | -2.8% |
| 2025-08-19 23:30 | 2025-08-18 | Parlavecchio Caryn | Officer - CHRO | SELL | $31.17 | 2,178 | $67,880 | 155,464 | -1.4% |
| 2025-07-18 23:15 | 2025-07-16 | FLIER JEFFREY S. | Director | SELL | $40.02 | 11,136 | $445,688 | 0 | -100.0% |
| 2025-07-11 04:46 | 2025-07-08 | Qatanani Mo | Officer - CHIEF SCIENTIFIC OFFICER | SELL | $34.44 | 24,066 | $828,898 | 115,495 | -17.2% |
| 2025-06-25 23:30 | 2025-06-23 | FLIER JEFFREY S. | Director | OPT+S | $32.58 | 31,452 | $1,024,722 | 11,136 | 0.0% |
| 2025-06-17 23:30 | 2025-06-16 | Peng Katie | Director | SELL | $31.97 | 3,031 | $96,888 | 34,920 | -8.0% |
| 2025-06-17 23:30 | 2025-06-16 | Qatanani Mo | Officer - CHIEF SCIENTIFIC OFFICER | SELL | $32.00 | 3,668 | $117,381 | 139,561 | -2.6% |
| 2025-06-17 23:30 | 2025-06-16 | Parlavecchio Caryn | Officer - CHRO | SELL | $32.00 | 6,186 | $197,961 | 157,642 | -3.8% |
| 2025-06-17 23:30 | 2025-06-16 | Ho Junlin | Officer - GENERAL COUNSEL | SELL | $32.00 | 7,442 | $238,154 | 222,569 | -3.2% |
| 2025-05-30 23:32 | 2025-05-29 | FLIER JEFFREY S. | Director | SELL | $29.73 | 6,075 | $180,584 | 24,070 | -20.2% |
| 2025-05-30 23:30 | 2025-05-29 | Reed Joshua | Director | SELL | $29.72 | 5,400 | $160,463 | 15,732 | -25.6% |
| 2025-05-30 23:31 | 2025-05-29 | Brudnick Richard | Director | SELL | $29.72 | 6,075 | $180,531 | 15,057 | -28.7% |
| 2025-05-30 23:31 | 2025-05-29 | Burow Kristina | Director | SELL | $29.72 | 5,400 | $160,511 | 21,071 | -20.4% |
| 2025-05-30 23:30 | 2025-05-29 | Vaishnaw Akshay | Director, Officer - President of R&D | SELL | $29.72 | 6,750 | $200,612 | 616,205 | -1.1% |
| 2025-05-30 23:31 | 2025-05-29 | Gilman Michael | Director | SELL | $29.72 | 3,375 | $100,304 | 55,216 | -5.8% |
| 2025-04-30 01:03 | 2025-04-25 | Sacco Tracey | Officer - Chief Commercial Officer | OPT+S | $32.83 | 5,000 | $164,131 | 71,750 | 0.0% |
| 2025-03-26 02:39 | 2025-03-24 | Sacco Tracey | Officer - Chief Commercial Officer | OPT+S | $33.08 | 6,500 | $215,014 | 71,750 | 0.0% |
| 2025-03-26 02:37 | 2025-03-24 | Moore Erin | Officer - Interim PFO and PAO | OPT+S | $33.12 | 13,564 | $449,237 | 82,609 | 0.0% |
| 2025-03-20 00:00 | 2025-03-17 | Peng Katie | Director | SELL | $34.42 | 1,006 | $34,627 | 30,319 | -3.2% |
| 2025-03-13 02:06 | 2025-03-10 | Myles Edward H | Officer - COO & CFO | OPT+S | $35.62 | 142,292 | $5,068,968 | 111,345 | 0.0% |
| 2025-02-21 03:55 | 2025-02-18 | Qatanani Mo | Officer - CHIEF SCIENTIFIC OFFICER | OPT+S | $37.37 | 72,645 | $2,714,765 | 111,084 | 0.0% |
| 2025-02-21 02:30 | 2025-02-18 | Parlavecchio Caryn | Officer - CHRO | SELL | $36.83 | 5,296 | $195,046 | 140,258 | -3.6% |
| 2025-02-21 01:53 | 2025-02-18 | Ho Junlin | Officer - GENERAL COUNSEL | SELL | $36.83 | 5,742 | $211,472 | 189,295 | -2.9% |
| 2025-02-21 01:41 | 2025-02-18 | Backstrom Jay T. | Director, Officer - CHIEF EXECUTIVE OFFICER | SELL | $36.83 | 18,372 | $676,622 | 311,991 | -5.6% |
| 2025-02-21 02:18 | 2025-02-18 | Myles Edward H | Officer - COO & CFO | SELL | $36.83 | 7,809 | $287,598 | 140,740 | -5.3% |
| 2025-01-22 00:35 | 2025-01-16 | Backstrom Jay T. | Director, Officer - CHIEF EXECUTIVE OFFICER | SELL | $44.20 | 22,308 | $985,951 | 330,363 | -6.3% |
| 2025-01-22 00:35 | 2025-01-16 | Marantz Jing L. | Officer - CHIEF MEDICAL OFFICER | SELL | $44.20 | 5,655 | $249,935 | 67,200 | -7.8% |
| 2025-01-22 00:35 | 2025-01-16 | Sacco Tracey | Officer - Chief Commercial Officer | SELL | $44.20 | 3,890 | $171,927 | 45,395 | -7.9% |
| 2025-01-22 00:35 | 2025-01-16 | Qatanani Mo | Officer - CHIEF SCIENTIFIC OFFICER | SELL | $44.20 | 7,347 | $324,717 | 135,421 | -5.1% |
How to Interpret $SRRK Trades
Not every insider transaction in Scholar Rock Holding Corp is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $SRRK shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for SRRK
Insider activity data for Scholar Rock Holding Corp is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $SRRK, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.